Applied Sciences
| Open Access |
DOI: In Silico Exploration of Natural Compounds and Drug Repurposing Strategies for FOXO3a Modulation in Metabolic and Autoimmune Muscle Disorders
Torsha Das , Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow Campus, Gomti Nagar Extension, Lucknow-226028, India Pragya Singh , Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow Campus, Gomti Nagar Extension, Lucknow-226028, India Enaya Tufail , Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow Campus, Gomti Nagar Extension, Lucknow-226028, India Somali Sanyal , Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow Campus, Gomti Nagar Extension, Lucknow-226028, IndiaAbstract
Chronic inflammation, oxidative stress, energy-defective intermediates homeostasis has been gradually recognized in their relevant diseases: metabolic disorders and autoimmune muscle disease including myositis. Forkhead box O3a (FOXO3a), an important transcription factor plays important role in regulating essential cellular processes such as stress response, apoptosis, metabolism homeostasis, and muscle protein turnover. Recent advances in computational biology have allowed for high-throughput screening of FOXO3a-targeting molecules in silico. Flavonoids and polyphenols are different subcategories of phytochemicals that gained attraction due to their remarkable antioxidant, anti-inflammatory, and multi-target abilities. At the same time, drug repurposing strategy is a cost-effective approach because it identifies new therapeutic uses for known approved drugs which have an established safety profile. Here, we review FOXO3a in metabolic and autoimmune muscle disease. It also emphasizes the use of in silico methods to screen phytochemicals and repurposed drugs that may target FOXO pathways as novel therapies for future pharmacologic development.
Keywords
FOXO3a, Therapeutic targets, Myositis, In Silico Drug Discovery, Drug repurposing, Phytochemicals
References
Accili, D., & Arden, K. C. (2004). FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell, 117(4), 421–426. https://doi.org/10.1016/S0092-8674(04)00452-0
Andersson, K. E. (2018). PDE5 inhibitors and nitric oxide–cGMP signaling. Pharmacological Reviews, 70(3), 601–649. https://doi.org/10.1124/pr.117.014928
Babalola, O.O., Bridget, K., Oyubu, G. et al. Integrating phytochemicals and in silico methods for modern drug discovery: a comprehensive review. Discov. Chem. 2, 297 (2025). https://doi.org/10.1007/s44371-025-00373-y
Brunet, A., Bonni, A., Zigmond, M. J., et al. (1999). Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell, 96(6), 857–868. https://doi.org/10.1016/S0092-8674(00)80595-4
Calnan, D. R., & Brunet, A. (2008). The FoxO code. Oncogene, 27(16), 2276–2288. https://doi.org/10.1038/onc.2008.21
Cheng, Z., Tseng, Y., & White, M. F. (2017). Insulin signaling meets mitochondria in metabolism. Trends in Endocrinology & Metabolism, 21(10), 589–598. https://doi.org/10.1016/j.tem.2010.06.005
Daina, A., Michielin, O., & Zoete, V. (2017). SwissADME: A free web tool to evaluate pharmacokinetics and drug-likeness of small molecules. Scientific Reports, 7, 42717. https://doi.org/10.1038/srep42717
Eijkelenboom, A., & Burgering, B. M. T. (2013). FOXOs: signalling integrators for homeostasis maintenance. Nature Reviews Molecular Cell Biology, 14(2), 83–97. https://doi.org/10.1038/nrm3507
Fasano, C., Disciglio, V., Bertora, S., et al. (2019). FOXO3a from the nucleus to the mitochondria: A round trip in cellular stress response. Cells, 8(9), 1110. https://doi.org/10.3390/cells8091110
Giordano, D., Biancaniello, C., Argenio, M. A., & Facchiano, A. (2022). Drug Design by Pharmacophore and Virtual Screening Approach. Pharmaceuticals (Basel, Switzerland), 15(5), 646. https://doi.org/10.3390/ph15050646
Greer, E. L., & Brunet, A. (2005). FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene, 24(50), 7410–7425. https://doi.org/10.1038/sj.onc.1209086
Habrowska-Górczyńska, D. E., Kozieł, M. J., Kowalska, K., & Piastowska-Ciesielska, A. W. (2021). FOXO3a and Its Regulators in Prostate Cancer. International Journal of Molecular Sciences, 22(22), 12530. https://doi.org/10.3390/ijms222212530
Kumar, S., & Pandey, A. K. (2013). Chemistry and biological activities of flavonoids: An overview. The Scientific World Journal, 2013, 162750. https://doi.org/10.1155/2013/162750
Li, Y., Wang, Y., Kim, E., et al. (2016). Bnip3 mediates the hypoxia-induced autophagy and apoptosis in cardiomyocytes. Cell Death & Disease, 7, e2570. https://doi.org/10.1038/cddis.2016.359
Lipinski, C. A., Lombardo, F., Dominy, B. W., et al. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery. Advanced Drug Delivery Reviews, 46(1–3), 3–26. https://doi.org/10.1016/S0169-409X(00)00129-0
Martins, R., Lithgow, G. J., & Link, W. (2016). Long live FOXO: unraveling the role of FOXO proteins in aging and longevity. Aging Cell, 15(2), 196–207. https://doi.org/10.1111/acel.12427
Meng, X. Y., Zhang, H. X., Mezei, M., et al. (2011). Molecular docking: A powerful approach for structure-based drug discovery. Current Computer-Aided Drug Design, 7(2), 146–157. https://doi.org/10.2174/157340911795677602
Morris, G. M., Huey, R., Lindstrom, W., et al. (2009). AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of Computational Chemistry, 30(16), 2785–2791. https://doi.org/10.1002/jcc.21256
Panche, A. N., Diwan, A. D., & Chandra, S. R. (2016). Flavonoids: An overview. Journal of Nutritional Science, 5, e47. https://doi.org/10.1017/jns.2016.41
Pushpakom, S., Iorio, F., Eyers, P. A., et al. (2019). Drug repurposing: Progress, challenges and recommendations. Nature Reviews Drug Discovery, 18, 41–58. https://doi.org/10.1038/nrd.2018.168
Rojas, C., Slusher, B. S., & Navari, R. M. (2010). Palonosetron: Pharmacology and clinical use. Expert Review of Anticancer Therapy, 10(8), 123–135. https://doi.org/10.1586/era.10.10
Sandri, M., Sandri, C., Gilbert, A., et al. (2004). Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1. Cell, 117(3), 399–412. https://doi.org/10.1016/S0092-8674(04)00400-3
Stitt, T. N., Drujan, D., Clarke, B. A., et al. (2004). The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases. Molecular Cell, 14(3), 395–403. https://doi.org/10.1016/S1097-2765(04)00211-4
Trott, O., & Olson, A. J. (2010). AutoDock Vina: improving the speed and accuracy of docking. Journal of Computational Chemistry, 31(2), 455–461. https://doi.org/10.1002/jcc.21334
Yang, S. H., Chang, C., & Lian, Z. X. (2019). Polymyositis and dermatomyositis - challenges in diagnosis and management. Journal of translational autoimmunity, 2, 100018. https://doi.org/10.1016/j.jtauto.2019.100018.
Zhao, J., Brault, J. J., Schild, A., et al. (2007). FoxO3 coordinately activates protein degradation pathways in muscle. Cell Metabolism, 6(6), 472–483. https://doi.org/10.1016/j.cmet.2007.11.004
Download and View Statistics
Copyright License
Copyright (c) 2026 Torsha Das, Pragya Singh, Enaya Tufail, Somali Sanyal
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.